glp 1 kidney disease GLP-1 receptor agonists are increasingly used to treat type 2 diabetes and obesity, and trials have shown reductions in cardiovascular risk and slowing of failure. Adverse events are mostly gastrointestinal ICYMI: GLP-1 Agonists Show Promise

Abdelrahman SA, Raafat N, Abdelaal GMM, Aal SMA (2023) Electric field-directed migration of mesenchymal stem cells enhances their therapeutic potential on cisplatin-induced acute nephrotoxicity in rats

KPV does something different

GLP-1 and PYY3-36 as complementary gut hormones in the regulation of appetite and energy balance

GHK-Cu: Copper tripeptide evaluated for up-regulation of growth factors (e.g., TGF-related pathways), collagen production, and antioxidant activity

Most patients experience increased energy and improved well-being within a short period after treatment

This specific side-effect makes GHRP-6 highly prioritized in research models involving cachexia, wasting syndromes, or intentional hyper-caloric ingestion protocols